interleukin cytokines
Celularity Begins Trial of NK Cell Therapy, Herceptin, Keytruda for HER2-Positive Gastric Cancer
The firm believes its engineered off-the-shelf allogeneic placental-derived NK cells can work synergistically with approved antibodies.
The proof-of-principle study demonstrated the feasibility of altering the microbiome to elicit anti-PD-1 response and shed light on which patients might benefit.